Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in...
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Taylor & Francis Group
2022-05-01
|
| Cyfres: | Human Vaccines & Immunotherapeutics |
| Pynciau: | |
| Mynediad Ar-lein: | http://dx.doi.org/10.1080/21645515.2021.1943987 |